NASDAQ:BLUE
Delisted

Bluebird Bio Stock News

etoro logo Buy BLUE
*Your capital is at risk
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Brossard, Québec--(Newsfile Corp. - September 5, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (OTCQB: BLTMF) (the "Company" or "Orbec") announces that it has entered into a debt settlement agreement wi
Brossard, Quebec--(Newsfile Corp. - August 11, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) ("Orbec" or the "Company") is pleased to announce the appointment of Mr. Jean-David Moore to
Brossard, Quebec--(Newsfile Corp. - July 14, 2025) - Mines d'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the successful completion of its 2,000+ metre spring 2025 drilling camp
June Occupancy Shows Continued Momentum in Execution of Clear, Compelling and Effective Strategy Set by Recently Refreshed, Fit-for-Purpose Board Election of Even a Single Ortelius Nominee Would Risk
Brossard, Quebec--(Newsfile Corp. - June 9, 2025) - Further to its news release dated April 24, 2025, Mines D'Or Orbec Inc. (TSXV: BLUE) ("Orbec" or the "Company") is pleased to announce that it has c
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed b
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carl
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“
Bluebird Bio (BLUE) came out with a quarterly loss of $2.66 per share versus the Zacks Consensus Estimate of a loss of $3.60. This compares to loss of $7.20 per share a year ago.
Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have am
Chibougamau, Quebec--(Newsfile Corp. - May 9, 2025) - Mines D'Or Orbec/Orbec Gold Mines (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the company is participating in the upcoming 121 Mining In
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tende
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE